Evidence map›Paper›PMID 42822006›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Structure-guided discovery of novel ERα-binding peptides with in vitro antiproliferative activity.

Ting Guo, Yan Zhang, Shudan Yang, Lili Yang, Qisheng Chen, Yuting Wang, Rongrong Dou, Donglan Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ting GuoInstitute of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Yan ZhangDepartment of Emergency, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Shudan YangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Lili YangDepartment of Gynecology and Obstetrics, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Qisheng ChenDepartment of Gynecology and Obstetrics, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Yuting WangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Rongrong DouPathology department, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Donglan YuanDepartment of Gynecology and Obstetrics, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uterine leiomyoma (UL) is an oestrogen-dependent tumour, and ERα is closely associated with abnormal proliferation of UL cells. This study used structure-guided virtual screening of a 59,319-member peptide library, followed by molecular docking, MST, MD simulation, MM/PBSA analysis, MTT assays, ERα knockdown, and RT-qPCR, to identify ERα-binding peptides. Four peptides showed ERα binding, among which Peptide-4 exhibited the lowest

Indexed as

Antineoplastic AgentsDrug DiscoveryEstrogen Receptor alphaPeptidesCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsESR1 protein, humanEstrogen Receptor alphaPeptidesERα-binding peptidemolecular dockingoestrogen receptor alphastructure-based virtual screeningUterine leiomyoma

Identifiers

PMID42822006
PMCPMC13637783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.